Scientific Publications Database

Article Title: People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses( )
Authors: Lapointe, Hope R.; Mwimanzi, Francis; Cheung, Peter K.; Sang, Yurou; Yaseen, Fatima; Umviligihozo, Gisele; Kalikawe, Rebecca; Speckmaier, Sarah; Moran-Garcia, Nadia; Datwani, Sneha; Duncan, Maggie C.; Agafitei, Olga; Ennis, Siobhan; Young, Landon; Ali, Hesham; Ganase, Bruce; Omondi, F. Harrison; Dong, Winnie; Toy, Junine; Sereda, Paul; Burns, Laura; Costiniuk, Cecilia T.; Cooper, Curtis; Anis, Aslam H.; Leung, Victor; Holmes, Daniel T.; DeMarco, Mari L.; Simons, Janet; Hedgcock, Malcolm; Prystajecky, Natalie; Lowe, Christopher F.; Pantophlet, Ralph; Romney, Marc G.; Barrios, Rolando; Guillemi, Silvia; Brumme, Chanson J.; Montaner, Julio S. G.; Hull, Mark; Harris, Marianne; Niikura, Masahiro; Brockman, Mark A.; Brumme, Zabrina L.
Date of Publication:2022
People living with human immunodeficiency virus with well-controlled viral loads on antiretroviral therapy and preserved CD4(+) T-cell counts mount strong, functional antibody responses to 2- and 3-dose coronavirus disease 2019 vaccination, including to Omicron. Monitoring responses over time remains important.Background Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19) vaccines remain incompletely characterized in people living with human immunodeficiency virus (HIV) (PLWH), as do initial responses to a third dose. Methods We measured antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, angiotensin-converting enzyme 2 (ACE2) displacement, and viral neutralization against wild-type and Omicron strains up to 6 months after 2-dose vaccination, and 1 month after the third dose, in 99 PLWH receiving suppressive antiretroviral therapy and 152 controls. Results Although humoral responses naturally decline after 2-dose vaccination, we found no evidence of lower antibody concentrations or faster rates of antibody decline in PLWH compared with controls after accounting for sociodemographic, health, and vaccine-related factors. We also found no evidence of poorer viral neutralization in PLWH after 2 doses, nor evidence that a low nadir CD4(+) T-cell count compromised responses. Post-third-dose humoral responses substantially exceeded post-second-dose levels, though Omicron-specific responses were consistently weaker than responses against wild-type virus. Nevertheless, post-third-dose responses in PLWH were comparable to or higher than controls. An mRNA-1273 third dose was the strongest consistent correlate of higher post-third-dose responses. Conclusion PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after 2- and 3-dose COVID-19 vaccination. Results underscore the immune benefits of third doses in light of Omicron.